Stornello M, Valvo E V, Vasques E, Leone S, Scapellato L
Centro per lo studio e la terapia dell'pertensione, Ospedale Generale Umberto l, Siracusa, Italy.
J Hypertens Suppl. 1989 Sep;7(7):S65-7. doi: 10.1097/00004872-198909007-00016.
Nine outpatients with mild to moderate arterial hypertension, type 2 diabetes mellitus and persistent macroalbuminuria were studied. After 1 month of placebo, the patients were treated with 50 mg captopril twice a day for the following 6 months. Blood pressure and urinary albumin excretion were significantly reduced but no relationship was found between these two variables. No changes were detected in the renal plasma flow, glomerular filtration rate, filtration fraction, renal vascular resistance or metabolic pattern. Captopril significantly reduced blood pressure and albuminuria without any change in the renal function. The decrease in albuminuria may be related to the reduction in blood pressure as well as to a direct effect of captopril on glomerular haemodynamics.
对9例患有轻至中度动脉高血压、2型糖尿病和持续性大量蛋白尿的门诊患者进行了研究。在服用1个月安慰剂后,患者在接下来的6个月中每天两次服用50毫克卡托普利。血压和尿白蛋白排泄量显著降低,但未发现这两个变量之间存在关联。肾血浆流量、肾小球滤过率、滤过分数、肾血管阻力或代谢模式均未检测到变化。卡托普利显著降低了血压和蛋白尿,而肾功能没有任何改变。蛋白尿的减少可能与血压降低以及卡托普利对肾小球血流动力学的直接作用有关。